{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:43:49Z","timestamp":1776087829710,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K20514"],"award-info":[{"award-number":["25K20514"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000179","name":"Office of the Director","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP50D031876"],"award-info":[{"award-number":["DP50D031876"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.rmed.2026.108774","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:51:26Z","timestamp":1773273086000},"page":"108774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Industry payments and prescribing patterns of antifibrotic therapy for idiopathic pulmonary fibrosis in the United States"],"prefix":"10.1016","volume":"255","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-4748","authenticated-orcid":false,"given":"Anju","family":"Murayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth S.","family":"Tarras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina M.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve P.","family":"Kanter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah C.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rmed.2026.108774_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.74","article-title":"Idiopathic pulmonary fibrosis","volume":"3","author":"Martinez","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"7","key":"10.1016\/j.rmed.2026.108774_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2026.108774_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108774_bib4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108774_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108774_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(\u00ae) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108774_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12890-021-01811-0","article-title":"Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States","volume":"22","author":"Dempsey","year":"2022","journal-title":"BMC Pulm. Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108774_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/M20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing? : a systematic review","volume":"174","author":"Mitchell","year":"2021","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.rmed.2026.108774_bib9","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1111\/liv.16111","article-title":"Pharmaceutical industry payments and prescriptions of direct acting antiviral drugs for hepatitis C virus infection","volume":"44","author":"Murayama","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.rmed.2026.108774_bib10","unstructured":"Centers for Medicare & Medicaid Services. Open Payments. https:\/\/openpaymentsdata.cms.gov\/. Accessed September 18, 2025."},{"issue":"9","key":"10.1016\/j.rmed.2026.108774_bib11","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108774_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.chest.2023.11.035","article-title":"Comparison of pirfenidone and nintedanib: post hoc analysis of the CleanUP-IPF study","volume":"165","author":"Kim","year":"2024","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.rmed.2026.108774_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.32331","article-title":"The ethics of industry-funded speakers' Bureaus\u2014how they disseminate innovation and could corrupt medicine","volume":"8","author":"Miller","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.rmed.2026.108774_bib14","article-title":"Pathways to Independence: towards producing and using trustworthy evidence","volume":"367","author":"Moynihan","year":"2019","journal-title":"BMJ"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126001423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:43:59Z","timestamp":1776084239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126001423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"alternative-id":["S0954611126001423"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108774","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Industry payments and prescribing patterns of antifibrotic therapy for idiopathic pulmonary fibrosis in the United States","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108774"}}